Skip to main content


U.S. flag
      An official website of the United States government
              Here’s how you know
        Here’s how you knowDot gov**Official websites use .gov**
                 A **.gov** website belongs to an official government organization in the United States.
                  HTTPS**Secure .gov websites use HTTPS**
                 A **lock** (A locked padlock) or **https://** means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites. 
  Menu Close
          
        








  
  
    

  
      

                                      About HHS
    
                        
                              
      
      
      Programs & Services
    
                        
                              
      
      
      Grants & Contracts
    
                        
                              
      
      
      Laws & Regulations Breadcrumb
    HHS
                              Coronavirus
                              COVID-19 Vaccines
 Navigate to:
  Coronavirus (COVID-19)
                                            
            
            Vaccines
    
                                                  
                                            
            
      
      
      
      Treatments
    
                                                  
                                            
            
      
      
      
      Testing
    
                                                  
                                            
            
      
      
      
      COVID-19 Care for Uninsured Individuals
    
                                                  
                                            
            
      
      
      
      Public Health EmergencyText resize icon

                    




COVID-19 Vaccines








  
  
    

  
      



COVID-19 vaccines are safe, effective, and free.

COVID-19 vaccines are available for free to everyone 6 months and older living in the United States, regardless of immigration or insurance status. Getting vaccinated is the best way to help protect people from COVID-19. Get vaccinated if you haven't. If you are fully vaccinated, get a booster when you are eligible.

Find COVID-19 vaccine information from CDC

How do I get a COVID-19 vaccine?

Text your **zip code** to **438829**
	Call **1-800-232-0233** (TTY 1-888-720-7489)
	Message & Data rates may apply. Terms of Service.
	Find a vaccine near youQuestions about COVID-19 vaccines?

It’s normal to have questions before you get vaccinated. Learn common myths and facts about COVID-19 vaccines.

COVID-19 Vaccine Milestones

October

***October 3, 2023***
FDA authorized the updated Novavax COVID-19 Vaccine, Adjuvanted (2023-2024 Formula) for individuals ages 12 and older

September

***September 11, 2023***
FDA approved and authorized the emergency use of the updated Moderna and -BioNTech COVID-19 vaccines formulated to better protect against currently circulating variants

April

***April 18, 2023***
FDA amended the emergency use authorization to simplify the vaccination schedule for bivalent Moderna and Pfizer-BioNTech COVID-19 vaccines

***April 24, 2023***
HHS Secretary issued a directive on simplified and expanded use of bivalent mRNA COVID-19 vaccines
                        2020 – 2022 Milestones
    December

***December 8, 2022***
FDA authorizes the emergency use of the updated (bivalent) Moderna and Pfizer COVID-19 vaccines for children ages 6 months and up.

***December 9, 2022***
HHS Secretary issued a directive on bivalent vaccines for children starting at 6 months of age

October

***October 13, 2022***
HHS Secretary issued a directive on bivalent COVID-19 vaccine booster doses for individuals ages 5 years and older.

September

***September 2, 2022***
HHS Secretary issued a directive on bivalent COVID-19 vaccine booster doses for individuals ages 12 years and older.

July

***July 13, 2022***FDA authorized emergency use of Novavax COVID-19 Vaccine, Adjuvanted for individuals 18 years of age and older.

***July 21, 2022***
HHS Secretary issued a directive on the use of a two-dose Novavax COVID-19 Vaccine, Adjuvanted for persons ages 18 years and older.

June

***June 17, 2022***
FDA authorized Moderna and Pfizer-BioNTech COVID-19 vaccines for children down to 6 months of age.

***June 18, 2022***
HHS Secretary issued a directive to expand eligibility of the Moderna COVID-19 vaccine for children 6 months through 5 years old and the Pfizer-BioNTech COVID-19 vaccine for children 6 months through 4 years old.

***June 24, 2022***
HHS Secretary issued a directive to expand eligibility of a two-dose series of the Moderna COVID-19 vaccine for children ages 6 years through 17 years, and an additional Moderna dose for children in that age group who are immunocompromised.

May

***May 17, 2022***
FDA expanded eligibility for the Pfizer-BioNTech COVID-19 vaccine to allow a single booster dose for children 5 through 11 years of age.

***May 23, 2022***
HHS Secretary issued a directive to expand eligibility for a single booster dose to children ages 5 through 11 years and updated the recommendation of a second COVID-19 vaccine booster dose to certain populations.

March

***March 29, 2022***CDC recommends additional boosters for certain individuals.

January

***January 10, 2022***
HHS Secretary issued a directive to expand eligibility for children ages 12 through 15 years to receive a booster dose of the Pfizer COVID-19 vaccine, and to allow a third vaccine dose for immunocompromised children 5 through 11 years of age.

***January 31, 2022***FDA approved the second COVID-19 vaccine, Spikevax (COVID-19 Vaccine, mRNA), which was previously known as Moderna COVID-19 Vaccine; the approved vaccine will be marketed as Spikevax for the prevention of COVID-19 in individuals 18 years of age and older.

December

***December 10, 2021***
HHS Secretary issued a directive to expand eligibility for adolescents ages 16 and 17 to receive a booster dose of the Pfizer COVID-19 vaccine.

November

***November 3, 2021***
HHS Secretary issued adirective to expand eligibility for children five years and older to receive an age-appropriate dose of the Pfizer COVID-19 vaccine.

***November 8, 2021***
A joint letter from HHS Secretary Becerra and Education Secretary Cardona is issued about how schools can support COVID-19 vaccination for children.

***November 21, 2021***
HHS Secretary issued a directive to expand eligibility for all adults ages 18 and older to receive a booster dose of COVID-19 vaccines.

October

***October 20, 2021***
FDA amended the emergency use authorizations (EUAs) to allow for a single booster dose the Moderna COVID-19 vaccine and Janssen (Johnson and Johnson) COVID-19 vaccine. FDA also authorized the use of heterologous (or "mix-and-match") booster dose of an available vaccine in eligible individuals following completion of primary vaccination with a different COVID-19 vaccine.

***October 22, 2021***
HHS Secretary issued a directive on Moderna and Janssen (Johnson and Johnson) vaccine boosters*

***October 29, 2021***
FDA authorized the emergency use (EUA) for the Pfizer-BioNTech COVID-19 Vaccine for the prevention of COVID-19 to include children 5 through 11 years of age.

September

***September 22, 2021***
FDA amended the emergency use authorization (EUA) to allow a single booster dose of the Pfizer-BioNTech COVID-19 vaccine to be administered at least six months after completion of the vaccine's primary series in certain populations.

***September 25, 2021***
HHS Secretary issued a directive to allow a booster dose of the Pfizer COVID-19 vaccine to certain populations.

August

***August 23, 2021***FDA approved the first COVID-19 vaccine, Comirnaty (COVID-19 Vaccine, mRNA), which was previously known as Pfizer-BioNTech COVID-19 Vaccine, for the prevention of COVID-19 disease in individuals 16 years of age and older.

May

***May 10, 2021***
FDA amended the emergency use authorization for the Pfizer-BioNTech COVID-19 vaccine to include adolescents 12 through 15 years of age.

April

***April 19, 2021***
The White House announced that all people age 16 and older are eligible for the COVID-19 vaccine.

March

***March 2, 2021***
Acting HHS Secretary directed that teachers, school staff, and child care workers are eligible for COVID-19 vaccinations*.

***March 17, 2021***
Acting HHS Secretary issued a directive to expand COVID-19 vaccine eligibility to all Americans* by May 1, 2021.

February

***February 27, 2021***
FDA issued the third EUA for use of the Janssen COVID-19 vaccine in persons aged 18 years and older for the prevention of COVID-19.

December

***December 11, 2020***
FDA issued the first emergency use authorization (EUA) for use of the Pfizer-BioNTech COVID-19 vaccine in persons aged 16 years and older for the prevention of COVID-19.

***December 14, 2020***
The first deliveries of the COVID-19 vaccines began.

***December 18, 2020***
FDA issued the second EUA for use of the Moderna COVID-19 vaccine in persons aged 18 years and older for the prevention of COVID-19.
                        COVID-19 Vaccine Development and Authorization

The federal government has been working since the pandemic started to develop, manufacture, and distribute safe and effective COVID-19 vaccines.

Years before the COVID-19 pandemic, scientists were already studying coronaviruses to find out how to protect against them. When the COVID-19 pandemic began, researchers were able to come up with vaccines for this new virus much faster because of work that was already happening.

FDA Authorization

The Food and Drug Administration (FDA) reviews and evaluates COVID-19 vaccines for quality, safety, and effectiveness. The FDA then issues Emergency Use Authorizations (EUAs) for certain vaccines that meet rigorous, science-based standards. The FDA determines that these vaccines are safe and effective for public use.

CDC Recommendation

After the FDA authorizes the emergency use of a vaccine, an independent panel of medical and health experts called the Advisory Committee on Immunization Practices (ACIP) provides recommendations and guidance to the Director of the Centers for Disease Control and Prevention (CDC) regarding the use of the vaccine.

FDA Approval

When the FDA approves a vaccine, it must undergo the agency's standard approval process for reviewing the quality, safety and effectiveness. The FDA's Center for Drug Evaluation and Research conducts an analysis of the benefits and risks to ensure the vaccine meets the FDA's standards for approval.

Equitable Access to COVID-19 Vaccines

During the COVID-19 pandemic, each state, tribe, and territory received allocations of vaccines and developed its own plan for distributing vaccines to people in their jurisdiction.

Vaccinations in the United States began on December 14, 2020.

To ensure the equitable distribution of COVID-19 vaccines, the federal government stood up programs to reach high-risk communities directly and quickly.

The Federal Retail Pharmacy Program sent doses to 21 pharmacy partners with over 40,000 activated stores, 40% of which are located in high-risk zip codes.
	The Health Center COVID-19 Vaccine Program allocated doses directly to community-based health centers who signed up to receive and administer COVID-19 vaccines. The program was open to more than 1,400 health centers nationwide. Over 91% of these health center patients were individuals or families living at or below 200% of the Federal Poverty Guidelines.
	The Rural Health Clinic COVID-19 Vaccine Distribution (RHCVD) Program distributed doses directly to Rural Health Clinics in medically-underserved rural communities.
	Tribal health programs and Urban Indian Organizations (UIOs) decided to receive vaccines either through the Indian Health Service (IHS) or through the State. To better understand the needs of American Indian and Alaska Native, HHS initiated tribal consultation in September 2020 to seek input from tribal leaders on COVID-19 vaccination planning for Indian Country.Vaccine Data

The CDC’s COVID Data Tracker shows the total number of COVID-19 vaccinations administered in the United States.

*This content is in the process of Section 508 review. If you need immediate assistance accessing this content, please submit a request to digital@hhs.gov. Content will be updated pending the outcome of the Section 508 review.

                    
  


Content created by Assistant Secretary for Public Affairs (ASPA) Content last reviewed March 13, 2024 Back to top
    Contact HHS
    
                        
                                            
      
      
      Careers
    
                        
                                            
      
      
      HHS FAQs
    
                        
                                            
      
      
      Nondiscrimination NoticeHHS Archive
    
                        
                                            
      
      
      Accessibility
    
                        
                                            
      
      
      Privacy Policy
    
                        
                                            
      
      
      Viewers & PlayersBudget/Performance
    
                        
                                            
      
      
      Inspector General
    
                        
                                            
      
      
      Web Site Disclaimers
    
                        
                                            
      
      
      EEO/No Fear ActFOIA
    
                        
                                            
      
      
      The White House
    
                        
                                            
      
      
      USA.gov
    
                        
                                            
      
      
      Vulnerability Disclosure Policy
        Sign Up for Email Updates

Receive the latest updates from the Secretary, Blogs, and News Releases.

Sign Up
  HHS Headquarters
          200 Independence Avenue, S.W.
                  Washington, D.C. 20201
                  Toll Free Call Center: 1-877-696-6775​